Correction to: BMC Cancer 21, 463 (2021)
https://doi.org/10.1186/s12885-021-08162-3
Anzeige
Following publication of the original article [1], the authors identified reference citation errors in Table 1. The corrected Table 1 is supplied below.
Table 1
All eligible studies and case reports of trastuzumab administration during pregnancy in breast cancer patients
Author | Treatment during pregnancy | Pathological type, Grade | Stage at Pregnancy | Age at BC diagnosis | Age at pregnancy | GA at trastuzumab | GA at delivery | Delivery | Fetal outcome | AEs during pregnnacy | Initial Staging | PFS | OS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Yildirim et al. 2018 (24) | Trastuzumab, Pertuzumab | IDC, ER: -, PR: -, HER2: + | IV (liver, lung bone) | 22 | 23 | Prior to pregnancy - 20th GA week | Not delivered | – | Elective abortion at 27th GA week | Oligohydramnios/Anhydramnios, Right renal agenesis, IUGR, Right adrenal gland hyperplasia | IV | NR | NR |
Rasenack et al. 2016 (25) | Trastuzumab | IDC, ER: +, PR: +, HER2: + | IV (retroperitoneal, supraclavicular, mediastinal, left hilar, upper abdominal LNs) | 25 | 29 | Prior to pregnancy – 24th GA week, 29th GA week | 35th + 5 week | Cesarean section | Healthy at 3 years old, 2735 g birth weight, Apgar 7/9/9 | Oligohydramnios at 24th week, Recovered after trastuzumab interruption, Reappeared at 29th week after 8th trastuzumab dose | pT2N0M0 (08/2004) | > 72 months | > 72 months |
Safadi et al. 2012 (26) | Trastuzumab, Vinorelbine | IDC scirrhous, ER: -, PR: -, HER2: +, Gr3 | IV (bone) | 32 | 32 | 30th GA week | 33th + 5 week | Cesarean section | Healthy at 13 months, 1990 g birth weight, Apgar 8/9/9 | Anhydramnios at 33 weeks | IV | > 13 | > 13 |
Mandrawa et al. 2011 (27) | Trastuzumab | IDC, ER: -, PR: -, HER2: +, | IV (brain) | 25 | 28 | Prior to pregnancy - 27th GA week (9 doses in total, 3510 mg) | 37 weeks | Vaginal delivery | Healthy at 28 months, 3060 g. Birth weight, Transient Tachypnoea of the newborn | Oligohydramnios at 25th week, recovered after 2 weeks, recurred in 3d trimester | TxN0M0 | 2,75 | > 52,25 months |
Roberts et al. 2010 (28) | Trastuzumab | IDC, ER: -, PR: -, HER2: +, Gr3 | T2N1M0 | 36 | 36 | 4th GA week to 21st GA week | 37 weeks | Vaginal delivery | Healthy, 3200 g birth weight, Mild Transient Tachypnoea of the Newborn and CPAP for 24 h | Cardiotoxicity (LVEF decline: 61 to 40%, CHF) | T2N1M0 | > 9,25 | > 9,25 |
Beale et al. 2009 (29) | Trastuzumab, Tamoxifen | IDC, ER: +, HER2: +, Gr3 | TxNxM0 | 28 | 29 | Prior to pregnancy - 22nd week, already received 9 doses of trastuzumab | 31 + 6 weeks | Cesarean section | Twin A: 1590 g, Apgar 5/8/9, Intubated at 8 min for respiratory failure, Chronic renal failure and chronic lung disease, Death due to respiratory distress at 3 months Twin B: Healthy at discharge, 1705 g, Apgar 8/10 Transient respiratory failure till day 3, Elevated creatinine | Severe oligohydramnios, recovered in Twin B but remained minimal in Twin A, Amnioinfusion in 30 + 2′ weeks, Premature rupture of membranes (PROM) | TxNxM0 | > 14 | > 14 |
Smith et Warraich 2009 (30) | Trastuzumab, Tamoxifen, Goserelin | IDC, ER: +, HER2: +, Gr3 | TxNxM0 | 35 | 35 | 7th GA week - 31st week | 37 weeks | Cesarean section | Severe pulmonary hypoplasia and atelectasis, 2690 g birth weight, Death at 40 min after extubation | Persistent anhydramnios from 28th GA week till delivery | TxNxM0 | > 14.25 | > 14.25 |
Pant et al. 2008 (31) | Trastuzumab | IDC, Gr2/3, ER: -, PR: -, HER2: + | IV (lung) | 30 | 32 | Prior to pregnancy -30th week, total dose 4200 mg | 32 + 1 weeks | Vaginal delivery | Healthy at 5 years old, Normal Apgar values, 1810 g birth weight | Oligohydramnios from 25 to 32d week, premature rupture of membranes (PROM) | IIA (T1N1M0)- Radical mastectomy & Lymph node dissection (2 years before) | NR | > 129.5 |
Witzel et al. 2008 (32) | Trastuzumab | IDC, ER: +, PR: -, HER2: +, Gr2. | IV (lung, brain) | 29 | 31 | Prior to pregnancy -27th GA weeks (9 cycles in total, total dose 56 mg/kg) | 27 weeks | Cesarean section | Severe respiratory distress and strong capillary leak syndrome, necrotizing enterocolitis, 1015 g birth weight, Apgar 8/7/6, Death due to multiple organ failure at 5 months | Oligohydramnios and severe vaginal bleeding at 27th GA week, | T2NxM0 After neoadjuvant: pT0N0M0 | > 1 | > 37.25 |
Sekar and Stone 2007 (33) | Trastuzumab, Docetaxel | IDC, ER: -, PR: -, HER2: +, Gr2 | IV (lung, brachial plexus) | 25 | 28 | 23d GA week - 27th GA week (docetaxel 380 mg total dose, 1385 mg trastuzumab total dose) | 36 + 2 weeks | Cesarean section | Healthy at delivery, 2230 g birth weight, Apgar 7/9 | Anhydramnios and IUGR at 30th GA week | T2N2M0 (Radical mastectomy & Lymphadenectomy | > 22 | > 100 |
Waterston and Graham (2006) (34) | Trastuzumab | IDC, Gr2, ER: -, PR: -, HER2: + | II (TxN1M0) | 30 | 30 | Prior to pregnancy – 3d GA week, total dose 523 mg during pregnancy | Term | Vaginal delivery | Healthy at delivery | No complications | II (TxN1M0) | > 9.25 | > 9.25 |
Fanale et al. 2005 (35) | Trastuzumab, Vinorelbine | IDC, Gr3, ER: -, PR: -, HER2: + | IV (liver) | 26 | 26 | 27th GA week - 34th GA week | 34 + 5 weeks | Vaginal delivery | Healthy at 6 months old, 2270 g birth weight, Apgar score 9/9/10 | Oligohydramnios | IIB (T2N1M0) | > 3 | > 18.75 |
Watson et al. 2005 (36) | Trastuzumab | IDC, ER: -, PR: -, HER2: + | T2N3M0 | 28 | 28 | Prior to pregnancy - 20th GA week | 37,5 weeks | Vaginal delivery | Healthy at 6 months old, 2960 g birth weight, Apgar score 8/9 | Anhydramnios | T2N3M0 | > 16.5 | > 16.5 |
Berwart et al. (2020) (37) | Trastuzumab, Tamoxifen | Left: IDC, ER: +, PR: +, HER2: + Right: IDC, ER: +, PR: +, HER2: - | T2N0M0 | 31 | 32 | Prior to pregnancy - 16th GA week Docetaxel: 20th GA week – 32d GA week | 38 weeks | Cesarean section | Healthy at 3 years old, 3820 g birth weight | No complications | T2N1M0 (Left mastectomy + Lymphadenectomy) | 12 | > 48 |
Safi et al. (2019) (40) | Trastuzumab, Docetaxel, Cyclophosphamide | NR | NR | NR | NR | 3d trimester | 36 weeks | Vaginal Delivery | Mild Respiratory distress, 2380 g birth weight, Apgar score 10, Admitted to Special Care Nursery (SCN) and discharged on day 4 | No complications | NR | NR | NR |
Aktoz et al. 2020 (41) | Trastuzumab, Docetaxel | IDC, ER: -, PR: -, HER2: + | IV (liver) | 37 | 37 | 22nd - 34th GA week (5 cycles) | 35 + 3 weeks | Cesarean section | Healthy at delivery, 2850 g birth weight, Apgar 8/8/9 | No complications | IV (liver) | > 3.5 | > 3.5 |
Lambertini et al. 2019 (42) | Patient 3: Trastuzumab, Brain RT Patient 4: Trastuzumab, Lapatinib, Tamoxifen (12 patients) | NR | NR | NR | Median:33 (30.0–36.5) | Patient 1,2: Prior to pregnancy – 3 months prior to pregnancy Patient 3,4: 1st trimester | Patient 3: 34 weeeks Median: 39 (36.5–39.5) | Patient 3: Cesarean section 3 Cesarean sections/ 1 vaginal delivery/ 1 missing | 7/12 (58.3%) Elective abortion No spontaneous abortions Median birth weight 3145 g (2880–3776) Apgar 8–9/9–10 | Patient1,2: No complications Patient 3: IUGR Patient 4: No complications No oligohydramnios No congenital malformations | NR | Patient 3: 1 Patient 4: - | Patient 3: 2 Patient 4: - |
Shlensky et al. 2017 (38) | Trastuzumab, Doxorubicin, Cyclophosphamide, Paclitaxel | IDC, ER: -, PR: -, HER2: + | IV | NR | NR | 15th GA week | 33 | Vaginal delivery | Healthy, Normal birth weight, 5 min Apgar score > 7 | Oligohydramnios at 33d GA week | IV | NR | NR |
Andrade et al. 2016 (39) | Trastuzumab | IDC, ER: -, PR: -, HER2: +, Gr2 | III (T3N2M0) | 31 | 32 | Prior to pregnancy – 27th GA week and then 28th -31st GA week (11 cycles in total, 4400 mg total dose) | 32 + 2 weeks | Cesarean section | Respiratory distress syndrome/Pulmonary infection, 1655 g birth weight, Apgar 4/10, Pulmonary hypertension/Persistence of the arterial canal Low creatinine clearance (6.1 ml/min), Healthy at 7 years old | Oligohydramnios at 27th GA week, Anhydramnios at 31st GA week | III (T3N2M0) | 32 | > 96 |
Pianca et al. 2015 (43) | Trastuzumab | IDC, ER: -, PR: -, HER2: +, Gr2 | T2N0M0 | 30 | 31 | 2d trimester – 28th GA week (2 cycles in total) | 37th week | Cesarean section | 2735 g birth weight, Apgar 4/8, O2 therapy at delivery, Healthy at 7 years old | Small abdominal circumference, Oligohydramnios at 29th GA week | T2N0M0 | > 11.75 | > 11.75 |
Gottschalk et al. 2011 (44) | Trastuzumab, Docetaxel, Carboplatin | IDC, ER: +, PR: +, HER2: +, Gr2 + DCIS | TxNxM0 | 38 | 38 | 14th GA week – 20th GA week weekly (7 cycles, 4 mg/kg) | 33 + 2 weeks | Cesarean section | Dystrophic premature neonate at delivery, birth weight < 3rd percentile, Postpartum normal development and renal function | Anhydramnios, Fetal renal failure at 21st GA week, IUGR at 28th week | TxNxM0 | > 5.9 | > 5.9 |
Azim et al. 2012 (20) | Trastuzumab (16 patients) | TxNxM0/ Non metastatic | NR | NR | 32.5 (26–40) | 3 months prior to pregnancy – during pregnancy | 40 (39–40) (n = 5) | NR | Healthy, Mean birth weight: 3485 (2940–4180), Mean Apgar score (10 min): 10 (9–10) | 7 (44%) induced abortions 25% (4/16) spontaneous abortions No oligohydramnios No congenital abnormalities | TxNxM0 | NR | NR |
Goodyer et al. 2009 (45) | Trastuzumab (2 patients) | Patient 1: ER: -, PR: -, HER2: + Patient 2: ER: -, PR: -, HER2: + | Patient 1: IV (pleural effusion) Patient 2: III | Patient 1: 30 Patient 2: 36 | NR | Patient 1: Second trimester – 29th GA week Patient 2: Prior to pregnancy – 6th GA week | Patient 1: 29 weeks Patient 2: 39 weeks | Patient 1: Cesarean section Patient 2: Vaginal Delivery | Patient 1: Respiratory distress syndrome and conductive hearing loss at delivery, Mild hypertonia and hyperreflexia, 1220 g birth weight, Healthy at 3 years old with ongoing minimal tightness of Achilles tendon Patient 2: Healthy at 2 years old, 2940 g birth weight, Events of gastroenteritis at 3, 8, 11 months | Patient 1: - Patient 2: 1 of 2 viable fetal sacs | Patient 1: TxN + M0 Patient 2: III | Patient 1: > 2 Patient2: > 24 | Patient 1: > 36 Patient2: > 24 |
Azim et al. 2009 (46) | Trastuzumab | IDC, ER: -, PR: -, HER2: +, Gr3 | II (T2N1M0) | 29 | 30 | Prior to pregnanacy - 1st GA week (1 cycle, 6 mg/kg) | 39 weeks | Cesarean section | Healthy at 14 moths old, 3550 g birth weight, | No complications | II (T2N1M0) | > 46 | > 46 |
Schoendorfer et Schaefer 2008 (47) | Trastuzumab | NR | IV (lung) | NR | 32 | Prior to pregnancy – 23d GA week | 27 + 4 weeks | Cesarean section | Multiple prematurity-related problems, Dysplastic/hypoplastic left kidney and renal congestion, Death at 4 months | Oligohydramnios at 23d GA week, Premature detachment of the placenta at 28th GA week | IV (lung) | > 8.25 | > 8.25 |
Shrim et al. 2007 (48) | Trastuzumab | IDC, ER: -, PR: -, HER2: +, Gr3 | IV (lung, brain) | 28 | 32 | Prior to pregnancy – 24th GA week (3200 mg total dose) | 37 weeks | Cesarean section | Healthy at 2 months old, 2600 g birth weight, Apgar 9/10, Transient tachypnea of the newborn, No maternal HF | Decreased maternal LVEF at 18th and 24th GA weeks | TxNxM0 | > 22 | > 100 |
Berveiller et al. 2008 (19) | Trastuzumab | ER: -, PR: -, HER2: + | III (T2N2bM0) | 43 | 45 | Prior to pregnancy (14 months, 2 mg/kg) | – | – | Voluntary abortion | Cervico-isthmic pregnancy | III (T2N2bM0) | > 23 | > 23 |
Bader et al. 2007 (49) | Trastuzumab, Paclitaxel | ER: -, PR: +, HER2: + | IV (bone mets, spinal cord compression) | 31 | 38 | 25th – 28th GA week (2 cycles, 14 mg/kg total dose) | 32 + 1 weeks | Cesarean section | Bacterial sepsis, transient renal failure, RDS at delivery, 1460 g birth weight, Healthy at 3 months | Anhydramnios and IUGR at 32d GA week | I | > 7.75 | > 16.75 |
Diakite et al. 2019 (22) | Trastuzumab | IDC, Gr2, ER: -, PR: +, HER2: + | T4N2aMx | 32 | 33 | Prior to pregnancy –first trimester | 33d GA week | Cesarean section | Twin A: Respiratory distress, 1450 g birth weight, Death at 10 days Twin B: 1550 g birth weight, Death at 40 days due to cardiorespiratory arrest | Fetal distress and oligohydramnios | T1NxMx | > 19.25 | > 19.25 |
Gupta et al. 2014 (21) | Trastuzumab, Paclitaxel (Dexamethazone, RT) | IDC, Gr3, ER: -, PR: -, HER2: + | IV (brain) | 24 | 24 | Prior to pregnancy – 12th GA week & 3d trimester – 6 weeks postpartum | 38 weeks | Cesarean section | Apgar 9/9, Healthy at 6 months old Maternal LVEF mildly decreased, Disease progression in brain mets/Leptomeningeal spread Death at 6 months postpartum | Brain metastases at 22nd GA week No fetal complications | T4N3cMx | 2.5 | 23 |
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.